Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Announces Agreement with Aegea Biotechnologies to Develop New, Highly Sensitive PCR-based COVID-19 Assay Utilizing Patented Switch-Blocker PCR Technology
Collaboration highlights the power and versatility of the proprietary Switch-Blocker technology, which may be applied to molecular diagnostics in COVID-19 and other infectious diseases, in addition to oncology applications currently commercialized and in development SAN DIEGO , Aug.
View HTML
Toggle Summary Biocept to Release Second Quarter 2020 Financial Results and Host Investor Conference Call on August 12, 2020
SAN DIEGO , Aug. 4, 2020 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
View HTML
Toggle Summary Biocept Reaches COVID-19 Testing Milestone with More than 7,000 Specimens Received and More than 6,500 Specimens Processed
Announces distribution of nearly 12,000 specimen collection kits to clients and has current availability of approximately 18,000 kits for immediate distribution   Expects Company-developed collection kits to be available later this quarter SAN DIEGO , Aug. 3, 2020 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Support Biocept Proposal to Authorize the Reverse Split of Common Shares
Stockholders requested to vote FOR Proposal SAN DIEGO , July 16, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer,
View HTML
Toggle Summary Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid
Company further expands its global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid the treatment of patients with cancer SAN DIEGO , June 30, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies
View HTML
Toggle Summary Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims
SAN DIEGO , June 24, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces it has entered into a managed care
View HTML
Toggle Summary Biocept Announces the Availability of 10,000 Specimen Collection Kits for RT-PCR COVID-19 Testing
SAN DIEGO , June 22, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000
View HTML
Toggle Summary Biocept to Relocate Corporate Offices and CLIA-Certified Laboratory to New San Diego Location
SAN DIEGO , June 5, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate
View HTML
Toggle Summary Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program
Target Selector™ platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid SAN DIEGO , May 29, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed
View HTML
Toggle Summary Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
SAN DIEGO , May 20, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W.
View HTML